evolution
In 2018
The company used its core technology to extend its strategy to the large variety and established Inner Mongolia Jingjing Biotechnology Co., Ltd., in the future, expanding the company's advantageous varieties and new products developed, further expanding the company's business scale and profitability.
In 2017
The company raised 240 million yuan with the help of the capital market platform, completing the company's core technology upgrade and industrial transformation, and its additive business steadily increased, with sales exceeding 50% of the overall revenue.
In 2016
The company established an academician workstation and a national and local joint engineering laboratory, and cooperated with Nobel Prize winner Dr. Murad to transform the results of cutting-edge biomedical technologies, marking the company's entry into a world-class amino acid leader into a new milestone.
In 2015
The company was successfully listed on the New Third Board and entered the innovation layer for the first time.
In 2014
The company successfully launched a series of products such as citrulline, arginine ketoglutarate, and ornithine aspartate developed using its core technologies. This extended the industrial chain of its advantageous products, formed a product echelon, and took a solid step towards entering the international market.
In 2013
The company passed the certification of high-tech enterprise. Its wholly-owned subsidiary, Shijiazhuang Jingjing Pharmaceutical Co., Ltd., successfully relocated and expanded production, and was among the first to pass the new version of GMP certification.
In 2012
Taking Jingjing Pharmaceutical Co., Ltd. (renamed from Xingtai Ruijingkang Biotechnology Co., Ltd.) as the main body, it integrated and reorganized affiliated companies, increased capital and shares to introduce strategic investors, and was restructured into a joint-stock company, establishing a standardized corporate governance system.
In 2010
To meet market demand, Shijiazhuang Jingjing Pharmaceutical Co., Ltd. launched an expansion and relocation project.
In 2009
The fermentation method arginine technology independently developed by Xingtai Ruijingkang Biotechnology Co., Ltd. passed the appraisal of scientific and technological achievements in Hebei Province: "This process fills a domestic gap, and the overall technical level reaches the leading level in China and the international advanced level."
In 2007
Xingtai Ruijingkang Biotechnology Co., Ltd. was registered and established, extending the industrial chain upstream.
In 2004
Shijiazhuang Jingjing Pharmaceutical Co., Ltd. passed GMP certification and officially entered the domestic pharmaceutical field.
In 2003
Shijiazhuang Jingjing Pharmaceutical Co., Ltd. was founded, the first sterile arginine production enterprise in China.
